Track Mineralys Therapeutics Inc. Common Stock — Monitor price, dividends, and performance in your free portfolio

Start Tracking Free

Mineralys Therapeutics Inc. Common Stock MLYS · Stock Open Mineralys Therapeutics Inc. Common Stock in new tab

15.33 USD
EPS
-4.30
P/B
2.76
ROE
-68.50
Beta
0.83
Target Price
43.56 USD
Mineralys Therapeutics Inc. Common Stock logo

Mineralys Therapeutics Inc. Common Stock

🧾 Earnings Recap – Q2 2025

Mineralys Therapeutics reported strong clinical trial results for lorundrostat, positioning it as a promising treatment for uncontrolled hypertension and related conditions, with significant interest from healthcare providers for future prescriptions.

  • Pivotal trial data from the Launch-HTN and Advance-HTN studies demonstrated significant reductions in systolic blood pressure, published in major medical journals.
  • A survey indicated that 95% of surveyed cardiologists and primary care physicians are likely to prescribe lorundrostat for patients with resistant hypertension if approved.
  • The company is actively preparing for a pre-NDA meeting with the FDA in Q4 2025, signaling readiness for regulatory submission.
  • Lorundrostat shows potential benefits in patients with comorbidities such as chronic kidney disease and obstructive sleep apnea, broadening its market application.
  • Ongoing pre-commercial efforts include enhancing market access and payer value assessments to support lorundrostat's launch.
📅
Loading chart...
Key Metrics
Earnings dateMarch 11, 2027
EPS-4.30
Book Value5.69
Price to Book2.76
Debt/Equity19.51
% Insiders0.729%
Estimates
Forward P/E-6.03
Forward EPS-2.60
Target Mean Price43.56

DCF valuation

Model fair value for Mineralys Therapeutics Inc. Common Stock (MLYS)
Result
Sign in to run the valuation for MLYS.
Assumptions
Growth– Capex– Tax– Terminal g– Cost of equity– Cost of debt–
Analyst price targets
9 analysts · consensus Strong buy · mean target 43.56 USD (low 19.00, high 56.00) · as of 12 Nov 2026
Low 19.00
Mean 43.56
High 56.00
Price 15.33
Published broker research as supplied by our market data feed, named by firm and dated; it does not identify individual analysts. Targets carry their last refresh date; rating changes can be a few days behind.

Mineralys Therapeutics Inc. Common Stock Logo Mineralys Therapeutics Inc. Common Stock Analysis (MLYS)

United States Health Care Official Website Stock

Is Mineralys Therapeutics Inc. Common Stock a good investment? Mineralys Therapeutics Inc. Common Stock (MLYS) is currently trading at 15.33 USD. Market analysts have a consensus price target of 43.56 USD. This suggests a potential upside from current levels.

Earnings Schedule: Mineralys Therapeutics Inc. Common Stock is expected to release its next earnings report on March 11, 2027. The market consensus estimate for Forward EPS is -2.60.

Investor FAQ

Does Mineralys Therapeutics Inc. Common Stock pay a dividend?

No, it does not currently pay a dividend.

What asset class is Mineralys Therapeutics Inc. Common Stock?

Mineralys Therapeutics Inc. Common Stock is classified as a Stock. You can compare it against its peer in the "Related Symbols" list.

When is the next earnings date?

The next earnings date is projected to be March 11, 2027. The company currently has a trailing EPS of -4.30.

Company Profile

Mineralys Therapeutics, Inc., a biopharmaceutical company, develops medicines to target diseases driven by dysregulated aldosterone in the United States. It is developing lorundrostat, a proprietary, orally administered, highly selective aldosterone synthase inhibitor for the treatment of cardiorenal conditions affected by dysregulated aldosterone, such as hypertension, chronic kidney disease, and obstructive sleep apnea. The company was formerly known as Catalys SC1, Inc. and changed its name to Mineralys Therapeutics, Inc. in May 2020. Mineralys Therapeutics, Inc. was incorporated in 2019 and is headquartered in Radnor, Pennsylvania.

Exchange Ticker
NMS (United States) MLYS
Trades
No dividend information available for this instrument.
Explore Premium Features

Unlock detailed news and exclusive insights with our Premium subscription.

See Pricing Plans

Fundamentals

Under Construction

This feature will be available soon. Stay tuned!

Follow us on Twitter for updates: @allinvestview

Check out our Roadmap for upcoming features.

Community Discussion